Tdap vaccine and pregnancy. Why is itimportant? Safety and efficacy of thevaccine

Descripción del Articulo

Pertussis (Bordetella pertussis) is a highly contagious respiratory disease that poses a significant threat to infants under six months of age, in whom clinical manifestations may be atypical and complications severe or fatal, including apnea, pneumonia, encephalopathy, and death. Despite the availa...

Descripción completa

Detalles Bibliográficos
Autor: Namizato Ikemiyashiro, Claudia Sofia
Formato: artículo
Fecha de Publicación:2025
Institución:Sociedad Peruana de Obstetricia y Ginecología
Repositorio:Revista Peruana de Ginecología y Obstetricia
Lenguaje:español
inglés
OAI Identifier:oai:ginecologiayobstetricia.pe:article/2773
Enlace del recurso:https://ginecologiayobstetricia.pe/index.php/RPGO/article/view/2773
Nivel de acceso:acceso abierto
Materia:Whooping cough
Pertussis
Bordetella pertussis
Tdap vaccine
Maternal vaccination
Tos ferina
Vacuna Tdap
Vacunación en el embarazo
Descripción
Sumario:Pertussis (Bordetella pertussis) is a highly contagious respiratory disease that poses a significant threat to infants under six months of age, in whom clinical manifestations may be atypical and complications severe or fatal, including apnea, pneumonia, encephalopathy, and death. Despite the availability of effective vaccines for decades, pertussis continues to be a public health problem, with recurring epidemic cycles.Since the childhood vaccination schedule is not completed until six months of age, newborns and infants remain vulnerable. Tdap vaccination during pregnancy has been shown to be an effective and safe strategy for preventing the disease at this stage. Administering the vaccine between 20 and 36 weeks of gestation—preferably at least two weeks before delivery—ensures adequate transplacental transfer of antibodies, conferring passive protection to the newborn. Numerous observationalstudies and meta-analyses have shown significant reductions in hospitalizations, severe illness, and mortality in infants born to vaccinated mothers. Likewise, no significant maternal, obstetric, or neonatal risks have been observed. Nor has maternal vaccination been shown to clinically interfere with the infant's immune response after receiving their own vaccination schedule. Vaccination coverage among pregnant women in Peru is still suboptimal, highlighting the need for health personnel to commit to recommending and implementing this intervention in every pregnancy as an integral part of prenatal care.
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).